Celsion Corporation (NASDAQ: CLSN) today announced data from the fourth cohort of patients in its Phase Ib dose escalating clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE